NEW YORK (Reuters) - The U.S. government will ship more of Gilead Sciences Inc's GILD.O antiviral treatment remdesivir to states experiencing an increase in COVID-19 cases including California, Texas, Florida and Arizona, according to the Department of Health and Human Services' website.
The government reallocated remdesivir to states with increasing cases, White House task force coordinator Deborah Birx said during a briefing on Friday.
HHS said on its website that the doses will ship starting Monday and extinguish the full amount of Gilead’s donation of 120,647 treatment courses. It said it would continue to work with Gilead to determine how the company’s anticipated inventory of 2 million doses by year’s end will be allocated.
California will receive 464 cases of 40 vials each, Texas will receive 448 cases of 40 vials, Florida will receive 360 cases of 40 vials and Arizona will receive 356 cases of 40 vials, according to the website.
Gilead donated the courses after the treatment received emergency use authorization from the U.S. Food and Drug Administration last month.
New York, which was one of the hardest hit states initially, was allocated 2,714 cases in total.
Reporting by Caroline Humer; Editing by Tom Brown
Our Standards: The Thomson Reuters Trust Principles.